CA
UTHR icon

Claro Advisors’s United Therapeutics UTHR Stock Holding History

Claro Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$383K Sell
707
-9
-1% -$5.07K 0.04% 336
2026
Q1 		$425K Buy
+716
New +$357K 0.05% 278

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Claro Advisors's UTHR Position: Q2 2026 in Review

Claro Advisors reduced its United Therapeutics (UTHR) stake by 1.3% in Q2 2026, selling an estimated $5.07K and leaving 707 shares worth $383K. The position accounts for 0.04% of the portfolio, ranked #336.

Claro Advisors first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $425K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Claro Advisors held 707 shares of United Therapeutics worth $383K as of Q2 2026.
  • Claro Advisors sold 9 United Therapeutics shares in Q2 2026, an estimated $5.07K.
  • United Therapeutics made up 0.04% of Claro Advisors's portfolio in Q2 2026, its #336 holding.
  • Claro Advisors first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Claro Advisors's United Therapeutics position peaked at $425K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Claro Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.